Journals in Pharmacology

51-60 of 72 results in All results

Pharmacological Research - Natural Products

ISSN: 2950-1997

Pharmacological Research - Natural Products (PRENAP) publishes original, replications (if relevant for the scientific community), and follow-up studies, as well as scope and systematic reviews and meta-analysis, of the pharmacological and toxicological properties of extracts and single molecules of natural origin, either isolated or synthesized, and its derivatives. PRENAP also welcomes pre-registration (phase-I) and phase-II registered reports in the field. The journal scope covers all fields of pharmacology and toxicology (experimental and clinical), pharmacognosy, ethnopharmacology, and phytochemistry of natural products. PRENAP is a sound-science journal, therefore novelty and perceived impact will not be considered in the evaluation process. However, the journal will focus on quality studies that advance our knowledge and will take measures to guarantee the replicability of the published material. Therefore, all natural extracts must be quantitatively characterized (minimum requirement is HPLC-MS) and included in the submission, either in the main text or supplemental material. The plants used must be identified in The Plant List, and a sample deposited in the hosting institution. The same procedures apply for products of other origin (animal, fungal, bacterial, etc), which must be identified and deposited properly. Studies employing human subjects or experimental animals must include the approval of institutional or national ethics committees, with process/protocol numbers, or a justification for not doing so. Reporting of experiments involving animals must comply to the ARRIVE guidelines. Experiments involving humans (patients or healthy volunteers) must be registered as clinical trial. All experimental dataset and code used in the articles must be made available in open repositories (such as Zenodo, FigShare, Mendeley Data, Data in Brief, etc.) upon submission, and a DOI number must be included in the accepted manuscripts, or a justification for not doing so must be provided. Appropriate statistical analysis must be included, consisting of main-effect parameters, number of biological units, replicas, and post hoc test from initial submission.

Pharmacological Research - Reports

ISSN: 2950-2004

Pharmacological Research Reports (PREREP) is a journal that publishes articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. We provide a venue through which specialists across disciplines can rapidly exchange information in health sciences that pertains to modern pharmacological topics. PREREP publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials). PREREP is a sound-science journal and therefore novelty and perceived impact will not be considered in the evaluation process. However, the journal will focus on quality studies that advance our knowledge and will take measures to guarantee the replicability of the published material.

Pharmacology & Therapeutics

ISSN: 0163-7258
5 Year impact factor: 13.7
Impact factor: 13.5

Pharmacology & Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology, including the actions of drugs, and/or the exploitation of drug targets. Disease pathophysiology is relevant provided it is part of a narrative around drug actions or new drug targets. Founded in 1976, Pharmacology & Therapeutics continues to be among the top 10 most cited journals in pharmacology.

Pharmacology Biochemistry and Behavior

ISSN: 0091-3057
5 Year impact factor: 3.5
Impact factor: 3.6

Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided. Benefits to authors We provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.

Phytomedicine

ISSN: 0944-7113
5 Year impact factor: 6.8
Impact factor: 7.9

International Journal of Phytotherapy and PhytopharmacologyPublished in affiliation with the European Scientific Cooperative On Phytotherapy (ESCOP) Phytomedicine is primarily a therapy-oriented Journal. Phytomedicine publishes innovative studies on efficacy, safety, quality and mechanisms of action of specified plant extracts, phytopharmaceuticals and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of specified herbal medicinal products, herbal preparations and purified compounds which have a defined and consistent quality assuring reproducible pharmacological activity. Phytomedicine was founded in 1994 to focus and stimulate research in this particular field and to set internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy and safety of phytomedicines. The main aims of Phytomedicine are associated with the integration of phytopreparations into conventional/official medicine. The journal covers the following sections: Clinical pharmacology and toxicology (randomized, placebo controlled, double blind, and observational open label studies) Behavioural, mental, affective, and stress-associated disorders Age-associated disorders Neuropharmacology Endocrine pharmacology Metabolic syndrome and obesity Cancer Immunopharmacology, inflammation Infectious diseases Pulmonary, gastrointestinal, cardiovascular and urogenital diseases Systems biology Safety assessment, pre-clinical toxicology, interaction with drugs and adverse events of herbal preparations Pharmacokinetic of natural compounds Standardization of herbal preparations Legislation of botanicals Invited reviews The directions of Phytomedicine are known to provide profound scientific background in Herbal Medicinal Products, their reproducible Quality and evidence based therapeutic efficacy. Since then quality criteria and standardization methods were defined and the European Medical Agency has elaborated numerous guidelines for the conduction of clinical studies and preparation of Herbal Medicinal Products. In total 107 ESCOP monographs have been produced and submitted to EMA. Many new analytical methods and instruments were implemented both for analysis and standardization of herbal Substances, herbal preparations and their bioassays and tremendous work has been carried out to remain aligned with these intentions during the last 18 years. Nowadays important topics remain to be approached, such as harmonization of the regulatory frameworks in Europe, America, Asia and Australia or the legislation of various "botanicals", where strict differentiation of requirements for health claims of herbal medicinal product, dietary supplements and nutraceuticals are required. Phytomedicine is the companion title to the open access journal Phytomedicine Plus.

Progress in Neuro-Psychopharmacology & Biological Psychiatry

ISSN: 0278-5846
5 Year impact factor: 5.3
Impact factor: 5.6

Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry - Psychedelics is a special section dedicated to research on psychedelics. Within this special section, the journal aims to publish reviews and research papers dealing with experimental and clinical aspects of psychedelics. More specifically, work describing mechanisms of action and pharmacological aspects of psychedelics as well as their effects on the nervous system is welcome. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Prostaglandins & Other Lipid Mediators

ISSN: 1098-8823
5 Year impact factor: 2.9
Impact factor: 2.9

Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators. Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology. Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt. US National Institutes of Health (NIH) voluntary posting ("Public Access") policy Prostaglandins & Other Lipid Mediators and Elsevier facilitate the author's response to the NIH Public Access Policy. For more details please see the Guide for authors Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Pulmonary Pharmacology & Therapeutics

ISSN: 1094-5539
5 Year impact factor: 3.1
Impact factor: 3.2

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology Before submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT: 1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics. Immediate rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies 2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controls Immediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work 3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human). 4. Inappropriate experiments or lacking essential detail Immediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time 5. Lack of novelty: The study must represent a novel approach to the field. Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the field Note that only manuscripts written in good English will be considered by the Editors (British usage is preferred).

Respiratory Investigation

ISSN: 2212-5345
5 Year impact factor: 2.7
Impact factor: 3.1

Official Journal of The Japanese Respiratory Society Respiratory Investigation formerly known as Nihon Kokyuki Gakkaizasshi (The Journal of the Japanese Respiratory Society) is the official English - language journal of the Japanese Respiratory Society. The journal published original manuscripts on clinical investigations of a variety of respiratory diseases and medicines, along with articles concerning basic physiology, pathology, and cellular/molecular biology relating to any pulmonary diseases. Our journal is particularly interested in publishing articles that focus on the diversity of disease manifestations based on genetic and/or environmental differences between the East and West. The journal will consider peer review and publish of pediatric pulmonology, if the manuscript closely related to respiratory disease in adults. Article types accepted include Original Articles, Rapid Communications, Reviews and Guidelines, Editorials, and Letters to the editor. A case report could be exceptionally accepted only when it contains significant scientific novelty and/or important clinical relevance. The journal enthusiastically welcomes contributions not only from Japanese members of our Society but also from non-members hailing from neighboring countries in Asia and anywhere worldwide.Please prepare manuscripts in conformance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/urm_main.html.)